Melissa Lyle, MD: Hello, everyone. I am Melissa Lyle, cardiology fellow at Mayo Clinic. Today, we will be discussing the management of Fontan patients. I am joined by my colleagues, Dr Alexander Egbe ...

Please provide your email address to receive an email when new articles are posted on . For the two-part UNIVERSE study, 12 children who underwent the Fontan procedure were enrolled in a single-arm ...

The Fontan operation and its variants have become the procedures of choice in patients with one anatomical or functional ventricular chamber. In a normal biventricular heart, the systemic and ...

PHILADELPHIA — In a phase 3 study, the phosphodiesterase-5 (PDE-5) inhibitor udenafil (Mezzion Pharma) did not improve the primary end point of oxygen consumption at peak exercise, but was associated ...

SEOUL, South Korea, Aug. 12, 2025 /PRNewswire/ -- A newly published post-hoc analysis of the landmark FUEL (Fontan Udenafil Exercise Longitudinal) Trial demonstrates that udenafil, a PDE5 inhibitor, ...

1. Which doctor should I consult for a Fontan procedure? You should consult a cardiac or heart surgeon for this procedure. 2. How long does the Fontan procedure take? Starting with administration of ...

Key method-of-use patent expected to extend U.S. protection for JURVIGO ® (udenafil) into the early 2040s, pending FDA approval and extensions FORT LEE, N.J., Dec. 3, 2025 /PRNewswire/ -- Mezzion ...

In 1968, Fontan and his colleagues successfully separated the pulmonary and systemic blood flow in a patient with tricuspid atresia by placing the circulations in series, with the single ventricle ...

Introduction: A hemodynamic derangement in Fontan circulation causes liver pathology known as Fontan-associated liver disease. Although liver biopsy is a standard for diagnosis of liver fibrosis, ...

A newly published, post-hoc analysis of the landmark FUEL (Fontan Udenafil Exercise Longitudinal) Trial demonstrates that udenafil, a PDE5 inhibitor, significantly improves peak oxygen consumption ...